Beijing, China, 19 May, 2021 – MicroPort Scientific Corporation (hereafter referred to “Microport®”, stock code: 00853) released the 4 year long-term follow-up results of the clinical trial of Firehawk® coronary rapamycin targeted eluting stent system (Firehawk®) in a broad all-comers population, referred to as ‘Target AC’. Professor Andreas Baumbach, Chair of Device Research and Director of Interventional Cardiology Research from the Heart Center of Queen Mary University of London, UK, revealed the results at 2021 EuroPCR.
In his presentation, Professor Baumbach stated that the 4 years target lesion failure occurred in compare groups of Firehawk® and Xience is 14.6% and 13.7% respectively, and no statistic difference(p-value=0.62). In addition, the results of the detail measurements fully agree with this composite end point. The cardiac death is 3.3% vs. 2.8%(P=0.54), the target vessel myocardial infarction is 9.2% vs. 9.3% (P=0.97), the ischemia-driven revascularization is 4.6% vs.5.7% (P=0.32) and the stent thrombosis rates is 2.3% vs. 2.9% (P=0.44). They are all no statistic difference.
These long-term follow up results strongly prove that Firehawk® and Xience are highly consistent in safety and effectiveness, allowing a step forward in international applications and providing a reliable choice for coronary heart disease patients and physicians worldwide.
About TARGET AC study
The TARGET AC trial is a prospective, multi-center, randomized controlled clinical trial consisting of entirely European based patients by MicroPort®. This clinical study enrolled its first patient in December 2015 and completed enrollment of its last patient in October 2016. In total, there were 1,653 patients enrolled from 21 clinical study sites throughout Europe including countries such as the United Kingdom, France, Spain, Italy, Belgium, the Netherlands, Poland, Germany, Austria and Denmark. The trial’s primary endpoint was the target lesion failure (TLF) rate at 12 months. In addition, the trial design included an Optical Coherence Tomography (OCT) sub-study consisting of 50 patients at 3 months post index procedure, as well as a QCA (Quantitative Coronary Angiography) sub-study consisting of 176 patients at 13 months. Patients enrolled in the TARGET AC trial will be followed for a duration of five years post index procedure.
MicroPort Scientific Corporation (Microport®) (stock code: 00853) is a leading medical device company that focuses on innovating, manufacturing, and marketing high quality and high-end medical devices globally. Founded in Shanghai in 1998 on the belief that every person has the right to high quality medical treatments, MicroPort® is today a global medical devices company with over 7,000 employees worldwide. MicroPort® provides solutions across twelve therapeutic areas, including orthopedics, cardiovascular rhythm management, electrophysiology, and endovascular, with therapeutic solutions available in more than 80 countries and over 10,000 hospitals around the world. Today, a patient benefits from a MicroPort® solution every six seconds. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.
For more information, please refer to: www.microport.com.